Cargando…

P1174: PI3K INHIBITOR LINPERLISIB COMBINED WITH GEMCITABINE AND OXALIPATIN (GEMOX) IN RELAPSED AND/OR REFRACTORY DLBCL: ANALYSIS BASED ON TUMOR BIOLOGY

Detalles Bibliográficos
Autores principales:	Zhi-Ming, LI, Sun, Peng, Cen, Hong, Yang, Hai-Yan, Huang, Rui, Cai, Zhen, Gu, Xue-Kui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430973/ http://dx.doi.org/10.1097/01.HS9.0000971592.88393.d2

Ejemplares similares

PB2272: PI3KΔ INHIBITOR LINPERLISIB FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL
por: Qiu, Lihua, et al.
Publicado: (2023)

PB2269: PI3KΔ INHIBITOR LINPERLISIB FOR ELDERLY PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL
por: Sun, Xiuhua, et al.
Publicado: (2023)

The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
por: Wang, Tingyu, et al.
Publicado: (2023)

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
por: Demols, A, et al.
Publicado: (2006)

P1119: THE ORAL PI3KΔ INHIBITOR LINPERLISIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: A SINGLE-ARM MULTICENTER PHASE 2 CLINICAL TRIAL
por: wang, T., et al.
Publicado: (2022)

Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma
por: Wang, Jing-hua, et al.
Publicado: (2016)

P1695: REAL-WORLD SURVIVAL, HEALTHCARE RESOURCE UTILIZATION, AND COSTS AMONG U.S. ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH R-GEMOX IN THE RELAPSED/REFRACTORY SETTING
por: Garg, Mahek, et al.
Publicado: (2023)

Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients
por: Vici, Patrizia, et al.
Publicado: (2013)

Adjuvant Gemcitabine-Oxaliplatin (GEMOX) after Curative Surgery in High-risk Patients with Cholangiocarcinoma
por: Paule, Bernard, et al.
Publicado: (2010)

Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL
por: Zhang, Jing, et al.
Publicado: (2023)

Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study
por: Hawkes, Eliza A., et al.
Publicado: (2021)

GOALs in relapsed DLBCL
por: Rösler, Wiebke, et al.
Publicado: (2022)

Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy
por: Rentsch, Vera, et al.
Publicado: (2022)

Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL
por: Torka, Pallawi, et al.
Publicado: (2022)

A Retrospective Case Series Of High-Intensity Focused Ultrasound (HIFU) In Combination With Gemcitabine And Oxaliplatin (Gemox) On Treating Elderly Middle And Advanced Pancreatic Cancer
por: Tao, Shuang-fen, et al.
Publicado: (2019)

Real-World Evidence on Palliative Gemcitabine and Oxaliplatin (GemOx) Combination Chemotherapy in Advanced Biliary Tract Cancer
por: Lagenfelt, Hanna, et al.
Publicado: (2021)

Comparative analysis of primary versus relapse/refractory DLBCL identifies shifts in mutation spectrum
por: Greenawalt, Danielle M., et al.
Publicado: (2017)

Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL
por: Shi, Hui, et al.
Publicado: (2022)

An Orthopedic Clinic of 1174 A.D.
por: Cravener, Edward K.
Publicado: (1931)

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
por: Chen, Xiaofeng, et al.
Publicado: (2020)

Genotyping on ctDNA Identifies Shifts in Mutation Spectrum Between Newly Diagnosed and Relapse/Refractory DLBCL
por: Liu, Hui, et al.
Publicado: (2020)

Extranucleolar CYCLON Staining Pattern Is Strongly Associated to Relapse/Refractory Disease in R-CHOP–treated DLBCL
por: Bouroumeau, Antonin, et al.
Publicado: (2021)

Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL
por: Jeyakumar, Nikeshan, et al.
Publicado: (2022)

Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context
por: Abdulhaq, Haifaa, et al.
Publicado: (2023)

Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL
por: Northend, Michael, et al.
Publicado: (2022)

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data
por: Sehn, Laurie H., et al.
Publicado: (2022)

P1213: SUBCUTANEOUS EPCORITAMAB WITH GEMOX INDUCED HIGH RESPONSE RATES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT
por: Wahlin, B. E., et al.
Publicado: (2022)

Gemcitabine, Navelbine, and Doxorubicin as Treatment for Patients with Refractory or Relapsed T-Cell Lymphoma
por: Qian, Zhengzi, et al.
Publicado: (2015)

Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma
por: Gutierrez, Antonio, et al.
Publicado: (2014)

Relapse timing is associated with distinct evolutionary dynamics in DLBCL
por: Hilton, Laura K., et al.
Publicado: (2023)

Comparison of Docetaxel + Oxaliplatin + S-1 vs Oxalipatin + S-1 as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Propensity Score Matched Analysis
por: Zhang, Xin, et al.
Publicado: (2020)

P1090: CAMRELIZUMAB (CAM) COMBINED WITH GEMOX CHEMOTHERAPY RESULTS IN HIGH COMPLETE METABOLIC RESPONSE RATES IN RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA (CHL): A PHASE II TRIAL
por: Xie, Y., et al.
Publicado: (2022)

CXCR4 can induce PI3Kδ inhibitor resistance in ABC DLBCL
por: Kim, Joo Hyun, et al.
Publicado: (2018)

Gemcitabine, Etoposide, Cisplatin, and Dexamethasone in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma
por: Kim, Ki-Hyang, et al.
Publicado: (2009)

High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma
por: Swoboda, Ryszard, et al.
Publicado: (2021)

Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden
por: Harrysson, Sara, et al.
Publicado: (2021)

The role of additional chemotherapy prior to autologous HCT in patients with relapse/refractory DLBCL in partial remission—A retrospective multicenter study
por: Shargian, Liat, et al.
Publicado: (2022)

P1120: NOVEL TARGETED AGENTS IN COMBINATION WITH R-ICE (R-ICE-X) BASED ON GENOTYPING IN RELAPSED/REFRACTORY DLBCL.
por: Yige, Shen, et al.
Publicado: (2023)

Correction to: High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin lymphoma
por: Swoboda, Ryszard, et al.
Publicado: (2021)

Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma
por: Houot, Roch, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e1ttd49cf1jm2gctg57csi8qkp